The study of the binding characteristics of σ ligands in vivo and in vitro requires radiolabeled probes with high affinity and selectivity. The radioligand presently used for in vitro studies of the σ 1 receptor, [ 3 H](+)-pentazocine, has significant limitations; it is difficult to synthesize, has limited chemical stability, and can be problematic to obtain. Evaluation of a series of novel 2(3H)-benzothiazolone compounds revealed SN56 to have sub-nanomolar and preferential affinity for the σ 1 subtype, relative to σ 2 and non-sigma, binding sites. The goal of this study was to characterize the binding of [ 
Introduction
The σ receptor was first identified as an opioid receptor subtype based on behavioral studies of morphine-like drugs in dogs (Martin et al., 1976) . Subsequent in vitro binding data revealed that this site represents a new class of non-opioid receptor (Tam, 1983) . To date, two subtypes of σ receptors (σ 1 and σ 2 ) have been identified based on differences in ligand selectivity, tissue distribution, and molecular characterization. The σ 1 receptor has been cloned from multiple species (Hanner et al., 1996; Kekuda et al., 1996; Mei and Pasternak, 2001; Pan et al., 1998; Seth et al., 1997 Seth et al., , 1998 ) and a significant number of ligands with high affinity and selectivity for it are available. The σ 2 receptor is less well characterized; it has not been cloned, and few specific ligands have been described.
The σ 1 receptor is involved in numerous physiological processes and disease states, and in vivo and in vitro studies indicate that modulation of σ 1 receptors using σ specific ligands can affect these systems (Cobos et al., 2008; Guitart et al., 2004; Hashimoto and Ishiwata, 2006; Maurice and Su, 2009) . Consequently, the σ 1 receptor is recognized as a potential medication development target and efforts to identify novel selective compounds are ongoing. While the σ 2 receptor may also represent a feasible drug development target, further research in this area will require the discovery of additional selective ligands for this subtype. The focus of the current work is therefore limited to the characterization of σ 1 binding. DeCosta et al. (1989) (Bowen et al., 1993) . [ 3 H](+)-Pentazocine exhibited low levels of non-specific binding and high affinity for σ 1 receptors (K d = 4.8 ± 0.4 nM), with N700 fold preference for the σ 1 over the σ 2 subtype (Bowen et al., 1993) . Efforts to design new σ 1 specific ligands have produced a limited number of radioprobes useful for exploring the pharmacology of the σ 1 receptor. Unfortunately, like [ 3 H](+)-pentazocine, each of the proposed new radioprobes exhibit limtations. Therefore, we sought to characterize the performance of SN56, a novel σ 1 selective, 2(3H)-benzothiazolone compound, as a tritiated radioligand for use in σ 1 competition binding experiments. SN56 exhibited sub-nanomolar affinity (K iσ1 = 0.56 nM) and N1000 fold selectivity for the σ 1 subtype relative to σ 2 and at least 350 times greater affinity for the σ 1 receptor European Journal of Pharmacology 653 (2011) 1-7 versus a battery of common receptors and transporters (Yous et al., 2005 
Materials and methods

Materials
Reagents and starting materials for the synthesis of SN56 were obtained from commercial suppliers and were used without purification. Precoated silica gel GF Uniplates from Analtech (Newark, DE) were used for thin-layer chromatography (TLC). Column chromatography was performed on silica gel 60 (Sorbent Technologies, Atlanta, GA). 1 H and 13 C NMR spectra were obtained on a Bruker APX400 (Billerica, MA) at 400 and 100 MHz, respectively. High resolution mass spectra (HRMS) were recorded on a Waters Micromass Q-Tof Micro mass spectrometer with a lock spray source (Milford, MA). Mass spectra (MS) were recorded on a Waters Acquity Ultra Performance LC (Milford, MA) with ZQ detector in ESI mode. Elemental analysis (C, H, N) was performed on a Perkin-Elmer CHN/SO Series II Analyzer (Waltham, MA). Chemical names were generated using ChemDraw Ultra (CambridgeSoft, version 10.0, Cambridge, MA) .
[ 3 H](+)-Pentazocine (29 Ci/mmol) was purchased from PerkinElmer (Boston, MS). (+)-Pentazocine, (−)-pentazocine, haloperidol, 1,3-di-o-tolylguanidine (DTG), bovine serum albumin (BSA) fraction V, sucrose, sodium chloride, tris(hydroxymethyl)aminomethane, 1N hydrochloric acid solution, and glacial acetic acid were purchased from Sigma-Aldrich (St. Louis, MO). Bio-rad Protein Assay reagent was purchased from Bio-rad (Hercules, CA). Ecoscint scintillation fluid and Brandel GF/B filter papers, 2.25 × 12.25 in. were purchased from Fisher Scientific (Pittsburgh, PA).
Synthesis of [ 3 H]-SN56
The design strategy for generating [ 3 H]-SN56 involved replacing a bromine atom on the aromatic ring of SN56 with a tritium atom (Fig. 1) . The preparation of the brominated precursor 4 is described below. Compounds 1 and 2 were prepared according to previously described procedures with minor modifications (Ucar et al., 1998; Yous et al., 1994) . Selective bromination of the 6-propylbenzo [d] thiazol-2(3H)-one 2 at the C-4 position was effected with bromine in acetic acid at room temperature. The bromo derivative was alkylated with 2-(hexamethyleneimino)ethylchloride in the presence of potassium carbonate in DMF to yield 4. Compound 4 was radiolabeled with tritium (30 Ci/mmol) by AmBios Labs, Inc. (Newington, CT).
Dimethylformamide (5.96 ml, 76.73 mmol) was added slowly to aluminium chloride (35.5 g, 264.6 mmol) with vigorous stirring. After 15 min, 2-hydroxybenzothiazole (5.4 g, 40 mmol) was added and the mixture was heated to 45°C. After 15 min, propionyl chloride (3.46 ml, 39.7 mmol) was added and the reaction mixture was heated to 85°C for 3 h. The hot mixture was then poured on ice; the crude product was collected by filtration, and washed with water. The solid was dissolved in ethyl acetate and the solvent was washed with water and brine, dried and evaporated. 99, 136.68, 134.23, 126.57, 123.24, 122.12, 111.22, 36.87, 24.30, 13.54 (3) Bromine (0.45 ml, 8.75 mmol) was added slowly to a solution of 2 (1.5 g, 7.76 mmol) in acetic acid (10 ml). The mixture was stirred 15 h at room temperature, poured into water and extracted with ethyl acetate (3 × 30 ml) . The combined organic layers were washed with a 10% solution of potassium carbonate followed by brine. The solution was dried over sodium sulfate and evaporated under vacuum. The residue was purified by chromatography on a silica gel column using petroleum ether/ethyl acetate (9:1) as the eluent to give 0.5 g (24%) of 4-bromo-6-propylbenzo[d]thiazol-2(3 H)-one as a white solid. 1 H NMR (CDCl 3 ): δ 9.29 (s, 1H), 7.26 (s, 1H), 7.12 (s, 1H), 2.56 (t, J = 7.6 Hz, 2H), 1.62 (m, 2H), 0.93 (t, J = 7.2 Hz, 2H).
13
C NMR (CDCl 3 ): δ 170. 45, 139.35, 132.22, 129.34, 124.44, 121.24, 103.90, 37.37, 24.48, 13.54 
3-(2-(
NaHCO 3 (0.51 g, 6.09 mmol) and 2-(hexamethyleneimino) ethylchloride hydrochloride (0.80 g, 4.06 mmol) were added, with mechanical stirring, to a solution of 3 (0.55 g, 2.03 mmol) in anhydrous DMF (15 ml). The reaction mixture was heated to 80°C for 1 h. After cooling, the mixture was poured into 80 ml of water, extracted with ethyl acetate (3 × 60 ml), and the combined organic layers were washed with brine and dried. The solvent was removed in vacuo, and the residue was chromatographed on a silica gel column using ethyl acetate/petroleum ether (4:6) as the eluent. 3-(2-(azepan-1-yl)ethyl)-4-bromo-6-propylbenzo[d]thiazol-2(3H)-one was isolated as a hydrochloride salt (white solid, 0.44 g, 49%) by addition of HCl/dioxane. 1 H NMR (DMSO-d 6 ): δ 10.81 (br s, 1H), 7.60 (s, 1H), 7.46 (s, 1H), 4.72 (t, J = 7.2 Hz, 2H), 3.47-3.24 (m, 6H), 2.56 (t, J = 7.5 Hz, 2H), 1.86 (br s, 4H), 1.67-1.55 (m, 6H), 0.88 (t, J = 7.2 Hz, 3H).
13 C NMR (DMSO-d 6 ): δ 170. 54, 138.87, 132.87, 132.63, 125.62, 121.79, 103.79, 56.73, 55.89, 43.14, 37.04, 28.58, 27.22, 24.51, 13.81 Fig. 2. 
Membrane preparation
Crude P 2 rat brain homogenates were prepared from male, Sprague Dawley rats (150-200 g) purchased from Harlan (Indianapolis, IN) as described previously (Matsumoto et al., 1995) . All procedures involving live animals were performed as approved by the Institutional Animal Care and Use Committee at the locations where the assays were performed. Briefly, unanesthetized rats were sacrificed by decapitation; brains minus cerebellum were harvested and maintained in ice cold 10 mM Tris-HCl/0.9% NaCl until processed. Tissues were homogenized with a Potter-Elvehjem homogenizer (5-10 strokes with motor driven Teflon pestle) in ice-cold 10 mM Tris-sucrose buffer (0.32 M sucrose in 10 mM Tris-HCl, pH 7.4) using 10 ml buffer per gram of tissue ×~3 g tissue/batch. Homogenates from multiple batches were combined and centrifuged for 10 min at 1000 ×g, at 4°C. Supernatants were decanted, combined and centrifuged for 15 min at 31,000 ×g, at 4°C. To reduce levels of bound endogenous ligand(s), the material from centrifugation at 31,000 ×g was washed as follows: 1) pellets were re-suspended in 10 mM Tris-HCl, pH 7.4 using 3 ml buffer per gram of tissue, 2) the resulting suspension was incubated for 30 min at 25°C, 3) following incubation, the suspension was centrifuged for 15 min at 31,000 ×g, at 4°C. The resulting pellets were re-suspended in Tris-HCl, pH 7.4 buffer at a final concentration of 1 g of tissue per 1.53 ml buffer. Tissue preparations were aliquoted in 1 ml portions and stored at −80°C. The Bradford assay was used to quantitate protein concentration (Bradford, 1976) .
Radioligand binding assays
Initial optimization of assay conditions was performed to maximize total binding and minimize non-specific binding. Parameters examined included evaluation of the buffer composition and pH, ratio of radioligand to membrane concentration, and determination of ligand and ligand concentration for defining non-specific binding. The following optimized conditions were used for subsequent studies reported below: 0.5 ml final sample volume, 90 min sample incubation at 25°C, Tris-HCl pH 8.0 (assay buffer), and 10 μM haloperidol (to define non-specific binding). Assay termination was effected by vacuum filtration through glass fiber filters on a 24 position Brandel cell harvester. Prior to use, filters were presoaked for 30 min in 0.5% polyethyleneimine to reduce non-specific binding. Following the initial filtration step, filters were washed in triplicate with 5 ml ice-cold 10 mM Tris-HCl, pH 8. The conditions determined from the preliminary studies were consistent with those reported in the literature for the analysis of σ 1 receptor binding using [ (Bowen et al., 1993; Hellewell et al., 1994; Matsumoto et al., 1996) . It should be noted that it was necessary to prepare [ 3 H]-SN56 spiking solutions in 1 mM HCl, to prevent non-specific binding of the radioligand to glass and plasticware, which was problematic with solutions prepared in the assay buffer. This requirement is not unprecedented and the small amount of acid has no impact on the final pH of the assay sample (Bylund and Toews, 1993) .
Association and dissociation assays
Association and dissociation studies were conducted to confirm that the binding kinetics of [ 3 H]-SN56 were appropriate for a 1-2 h incubation and processing by filtration. Kinetic studies were performed with 0.8 nM [
3 H]-SN56 and 100 μg membrane. For determination of association rates, samples were incubated for times ranging from 5 min to 2 h prior to filtration. For determination of dissociation rates, membranes were incubated for 120 min with [ 3 H]-SN56 prior to the addition of 100 μM (final concentration) haloperidol, followed by filtration at times ranging from 30 min to 4 h from the addition of haloperidol. The assays were performed in duplicate and repeated three times.
Saturation binding assays
For the determination of K d and B max by saturation binding, ten concentrations ranging from 0.01 to 0.8 nM of [ 3 H]-SN56 were tested per experiment with 100 μg membrane per sample. Non-specific binding was determined by the addition of haloperidol, at a 100 μM final concentration. Samples for the determination of total and nonspecific binding for each experiment were run concurrently and filtered simultaneously.
Competition binding assays
For the determination of K i for established σ ligands by competition binding, aliquots of membrane were incubated with ]-SN56 with 100 μg membrane per sample. Non-specific binding was determined by the addition of haloperidol, 100 μM final concentration. Samples for the determination of total and non-specific binding for each experiment were run concurrently and filtered simultaneously.
Scintillation counting and data analysis
Following washing, filters were transferred to scintillation vials and 5 ml scintillation cocktail was added. Filters were allowed to soak in cocktail for a minimum of 10 h prior to counting.
The data were analyzed using GraphPad Prism software (San Diego, CA). Saturation binding data were fit using nonlinear regression to a one site model. Association kinetics data were fit using linear regression of the plot of ln(B e − B/B e ) versus time, where B e = radioligand bound at equilibrium, and B = radioligand bound at time t; the slope of the plot yielded k obs . The association rate constant (k + 1 ) was calculated using the pseudo first-order method from the equation 
Results
Basic binding parameters
At near saturating conditions, non-specific binding of [ 3 H]-SN56 remained constant in the presence of 25 to 200 μg membrane, suggesting that the observed non-specific binding is due primarily to radioligand binding to the filter. Total binding was linear from 50 to 200 μg membrane (Fig. 3) .
Association and dissociation kinetics
From the association studies, k obs =0.080 min − 1 and k +1 =9.05×
. From the dissociation studies, k − 1 =0.0076 min − 1 and t 1/2 =91 min. The K d calculated from k − 1 /k +1 was 0.084 nM. The low dissociation rate permits the use of filtration for the separation of free from bound radioligand (Bylund et al., 2004) , while the association rate supports 90 min incubations for attaining steady-state binding. Bowen et al. (1993) . For the group of hallmark σ ligands tested, there was a significant correlation between the affinities obtained using the novel versus conventional radioligand. Of particular note is the higher affinity of (+)-pentazocine as compared to (−)-pentazocine in the assays, a stereoselectivity pattern that is consistent with binding to σ 1 receptors.
Saturation binding
Competition binding
Discussion
Characterization of a series of novel 2(3H)-benzothiazolone compounds in σ receptor competition binding assays revealed SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one) to have sub-nanomolar affinity and N1000 fold selectivity for the σ 1 subtype relative to σ 2 (Yous et al., 2005) . Binding of SN56 to non-σ binding sites was tested with a battery of receptors and transporters including, adrenergic α 1 , adrenergic α 2 , adrenergic β 1 , adrenergic β 2 , histamine H 1 , histamine H 2 , mu opioid, delta opioid, kappa opioid, dopamine D 1 , dopamine D 2 , serotonin 5HT 2a , serotonin 5HT 3 , GABA A , dopamine transporter, and serotonin transporters. Of the binding sites tested, only α 2 and H 1 showed affinities greater than 1 μM (K iα2 = 205 nM, and K iH1 = 311 nM respectively) (Yous et al., 2005) ; however, the affinity of SN56 for the σ 1 receptor is approximately 350 times higher than its affinity for either of these receptors, indicating a favorable selectivity profile for the development of a radioprobe for use in radioligand binding studies.
In membranes prepared from rat brain (data not shown). These values arẽ 5 fold higher than the affinity determined with saturation and kinetic studies of [ 3 H]-SN56 (~0.07 nM and~0.08 nM respectively). We suspect that depletion of the non-labeled ligand results in an erroneously high value for the K i of SN56 as determined by competition binding.
Systematic errors resulting from the use of high receptor concentrations may also contribute to errors in both the determination of K d from saturation and kinetic experiments, and in the determination of K i s of un-labeled compounds. However, these errors are minimal, quantifiable, and in practice when [ 3 H]-SN56 is used for competition binding assays of σ 1 ligands, our preliminary results suggest they have no impact on our K i determinations as compared to historical data for the compounds tested.
While most researchers are familiar with radioligand depletion due to excessive receptor concentration, depletion of the un-labeled ligand occurs when the affinity of the un-labeled compound greatly exceeds the affinity of the labeled compound (Chang et al., 1975; Goldstein and Barrett, 1987) . Goldstein and Barrett (1987) used computer modeling to derive estimates of the error in the determination of K i of ligands exhibiting higher affinities than the radioligands utilized in their measurement; the authors projected that for an un-labeled ligand with a true affinity 100 times greater than the radioligand (as in our case), 10% radioligand depletion would result in an experimentally determined K d~6 times higher than the true value. Thus, the~5 fold difference between the affinity of SN56, as determined by competition binding, and the affinity of [ 3 H]-SN56 determined with saturation and kinetic studies may be explained by this phenomena.
Practical considerations dictated that we use relatively high receptor concentrations; this introduces systematic error that is quantifiable and within acceptable limits. When possible, experimental conditions for binding experiments should be chosen so that the receptor concentration is less than 10% of the K d of the radioligand to minimize radioligand depletion (Chang et al., 1975) . However, with a radioligand with subnanomolar affinity this would require multi-milliliter sample volumes. Our experiments required 100 μg of tissue to obtain adequate signal for precise detection. We chose 0.5 ml sample volumes because we intend to adapt this method to a higher throughput 96-well method where sample volumes are more limited than in test tube based binding determinations. To ensure that N90% of added radioligand was "free" (unbound) in competition binding experiments run under these conditions, we utilized high concentrations of [ 3 H]-SN56. While these conditions are not ideal, they are tolerated if required for detection and the error in values obtained with the method are known and within an acceptable range (Carter et al., 2007) . Carter et al. (2007) (Matsuno et al., 1996) and BHDP (Klouz et al., 2003) , have been studied in rat brain membranes in tritiated and unlabeled forms and exhibit approximately 100 fold higher affinity for σ 1 versus σ 2 with no significant binding to other common receptors or transporters (Klouz et al., 2003; Matsuno et al., 1996) . However, differences in relative expression of σ 1 versus σ 2 in disease states, tissues, or cell lines may compromise the accurate analysis of σ 1 binding with these radioligands since their σ 1 /σ 2 selectivity ratios just meet the 100 fold difference generally accepted as the minimum difference required for discriminating receptor subtypes. Because [ 3 H]-SN56 displays a N1000 fold higher affinity for σ 1 versus σ 2 , changes in σ expression would not impact measurements performed with this radioligand as much as with the other proposed alternatives.
In vitro binding studies with receptor specific radioligands have historically been important in the discovery and characterization of receptors, and continue to play a central role in the process of drug discovery. Application of this technology to the σ receptor has resulted in: 1) identification of σ receptors as a unique receptor type (Su, 1982; Tam, 1983) , 2) confirmation that σ receptors have at least two subtypes Hellewell and Bowen, 1990) , and 3) determination of its anatomical distribution (Hellewell et al., 1994; Jansen et al., 1991a,b; Walker et al., 1992) . Radioligand binding studies continue to play a primary role in selecting σ ligands for in vivo testing because there are no widely accepted in vitro functional assays for σ 1 activation. In addition to its service in the initial characterization of the σ receptor, radioligand binding data has contributed to the elucidation of 1) structural elements that define high affinity σ 1 ligands, and 2) specific amino acids of the σ 1 protein that are critical for selective, high affinity binding of known ligands (Ablordeppey et al., 2000 (Ablordeppey et al., , 2002 Glennon, 2005; Seth et al., 2001; Yamamoto et al., 1999) . Studies correlating structure with binding affinity are ongoing; numerous examples of such labors have been reported in the literature, with the majority of effort focused on identifying subtype specific ligands (de Costa et al., 1992; Holl et al., 2009; Mesangeau et al., 2008; Zampieri et al., 2009) .
σ 1 Radioligands have also demonstrated utility in radio-imaging studies; several examples of the successful use of the σ 1 radioligand [ 11 C-SA4503] as a positron emission tomography (PET) imaging agent have been reported in recent years (Ishikawa et al., 2007; Rybczynska et al., 2009; Toyohara et al., 2009 ). Displacement of [ 11 C]-SA4503 by the σ 1 active antidepressant fluvoxamine confirmed that fluvoxamine occupies σ 1 receptors in healthy human male volunteers (Ishikawa et al., 2007) . Other studies showed reduced σ 1 receptor density in defined brain regions of Alzheimer's and Parkinson's patients (Toyohara et al., 2009) . Also, supporting a role for σ 1 in cancer, Rybczynska et al. (2009) reported that steroid hormones that are known σ 1 ligands displace [
11 C]-SA4503 from tumors in rats (Rybczynska et al., 2009) . Thus, these studies suggest σ 1 radioligands may hold significant diagnostic value for psychiatric diseases and cancer.
Future advances in the field of σ receptor therapeutic development will require greater knowledge of the nature of the interaction of the σ receptor with its ligands and protein binding partners. Additional tools needed to further this knowledge include new subtype specific agonist and antagonist ligands, radioligands, and other affinity labels and probes. The development of other technologies, such as high throughput methods for the determination of binding affinities, and in vitro functional assays, will also hasten efforts to design and identify new selective σ ligands with potential therapeutic value.
In conclusion, the results of our studies suggest that [ 
